首页> 外文OA文献 >Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)

【2h】

Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)

机译：广义焦虑症非抑郁患者的长期疗效和治疗症的安全性。一个26周的随机双盲安慰剂控制并行组在含有胍盐碱的开放标签期间（25毫克/天，致盲剂量调节至50毫克/天）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Istvan Bitter;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. lEfficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study [J] . Stein Dan J., Ahokas Antti, Jarema Marek, European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology . 2017,第5期

机译：Agomelatine（10或25毫克/天）在非抑郁的外焦虑症患者中的讲解和安全性：12周，双盲，安慰剂对照研究
2. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50?mg/day) versus escitalopram (10–20?mg/day) in out-patients with severe generalized anxiety disorder [J] . Dan J. Stein, Jon-Paul Khoo, Antti Ahokas, European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology . 2018,第8期

机译：12周的双盲随机化多中心研究患有严重的广泛焦虑症的Out-患者患者的疗效和安全性的疗效和安全性（25-50？mg /天）
3. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50 mg/day) and escitalopram (10-20 mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study [J] . Udristoiu T., Dehelean P., Nuss Ph, Journal of affective disorders . 2016,第Null期

机译：在患有严重抑郁症的门诊患者中，阿美美拉汀（25-50 mg /天）和依西酞普兰（10-20 mg /天）对一般人群的早期疗效以及短期抗抑郁药的疗效和安全性。一项为期12周的随机双盲比较研究
4. Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week Flexible-Dose Open-Label Extension to a 40-Week Double-Blind Randomised Placebo-Controlled Core Study [O] . Y. Ginsberg, T. Arngrim, A. Philipsen, -1

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周灵活剂量开放标签扩展到40-周双盲随机安慰剂对照核心研究
5. A study to determine the maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder. A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period. [O] . Frederic Rouillon 2013

机译：一项研究，以确定治疗杂种碱疗效以防止患有重症抑郁症的患者复发。 AGOMELATINE的8至10周的开放期治疗，然后是24周随机化双盲期，安慰剂控制，平行组和20周的可选双盲治疗期。

著录项

相似文献

相关主题

期刊订阅